Yeast Double-stranded RNA Virus L-A Deliberately Synthesizes RNA Transcripts with 5’-Diphosphate

Received for publication, April 28, 2010, and in revised form, May 27, 2010. Published, JBC Papers in Press, May 28, 2010, DOI 10.1074/jbc.M110.138982

Tosutomu Fujimura and Rosa Esteban

From the Instituto de Microbiologia Bioquímica/Departamento de Microbiología y Genética, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca 37007, Spain

L-A is a persistent double-stranded RNA virus commonly found in the yeast Saccharomyces cerevisiae. Isolated L-A virus synthesizes positive strand transcripts in vitro. We found that the 5’ termini of the transcripts are diphosphorylated. The 5’-terminal nucleotide is G, and GDP was the best substrate among those examined to prime the reaction. When GTP was used, the triphosphate of GTP incorporated into the 5’-end was converted to diphosphate. This activity was not dependent on host CTL1 RNA triphosphatase. The 5’-end of the GMP-primed transcript also was converted to diphosphate, the β-phosphate of which was derived from the γ-phosphate of ATP present in the polymerization reaction. These results demonstrate that L-A virus commands elaborate enzymatic systems to ensure its transcript to be 5’-diphosphorylated. Transcripts of M1, a satellite RNA of L-A virus, also had diphosphate at the 5’ termini. Because viral transcripts are released from the virion into the cytoplasm to be translated and encapsidated into a new viral particle, a stage most vulnerable to degradation in the virus replication cycle, our results suggest that the 5’-diphosphate status is important for transcript stability. Consistent with this, L-A transcripts made in vitro are resistant to the affinity-purified Ski1p 5’-exonuclease. We also discuss the implication of these findings on translation of viral RNA. Because the viral transcript has no conventional 5’-cap structure, this work may shed light on the metabolism of non-self-RNA in yeast.

The 5’-cap (m7GpppXp) and 3’-poly(A) tail structures are the hallmark of eukaryotic mRNAs and have important biological functions in promoting stability in the nucleus, transport to the cytoplasm, and translation and stability in the cytoplasm. Therefore, many viruses furnish their transcripts with the 5’-cap structure utilizing their own or cellular enzymes or even by snatching the structure from cellular mRNAs (1–3). Transcripts made by T7 RNA polymerase are recognized as foreign and induce innate immune responses in animal cells. Recent studies suggest that the 5’-triphosphate of the transcripts as well as secondary structure, are involved in these responses (4, 5). Therefore, the 5’-end of RNA bears important information concerning on self or non-self for the host cells.
**5'-Diphosphate Terminus of L-A Transcript**

virus from cells at a high frequency. In the replication cycle of L-A virus, only positive strand transcripts are released from virions into the cytoplasm. We therefore reasoned that the L-A transcript at this stage is vulnerable to the SKI1 5'-exonuclease. The nuclease requires 5’-monophosphorylated RNA as substrate, whereas the 5’-end of L-A transcript has not been well established. It was reported about three decades ago that the 5’ terminus was triphosphorylated (23) or diphosphorylated (24). Here, we establish that L-A has diphosphate at the 5’-end. More significantly, we demonstrate that the phosphate group of GTP or GMP, when the nucleotide was incorporated at the 5’-end of the transcript, was converted to diphosphate. The virus, thus, clearly avoids 5’-triphosphorylated or -monophosphorylated transcripts. Our work may shed light on the metabolism of non-self-RNA in yeast, especially on the role of phosphate groups at the RNA 5’-end.

**EXPERIMENTAL PROCEDURES**

**Strains and Media**—Strain 2404 (α kar1-1 his4, L-A-HN, L-BC, M-o) was used to obtain wild type L-A virions. 2927 (a ura3 trpl his3 ski2-2, L-A-0 L-BC-o) was used to prepare an L-A-free cell extract. A ctt1Δ strain was obtained from a haploid deletion series (BY4741 (a ura3Δ0 leu2Δ0 his3Δ1 met15Δ0 20 S RNA-o, 23 S RNA-o, L-A) background) of the EUROFAN collection. The L-A-free killer strain (a trpl ura3 leu2 his3 pep4::HIS3 nuc1::LEU2, L-A-o, M1, L-BC, pAB2) was obtained from Reed B. Wickner (25). L-A proteins expressed from plasmid pAB2 support replication of M1 in this strain. Cells were grown in rich YPAD medium (1% yeast extract, 2% peptone, 0.04% adenine sulfate, and 2% glucose) or synthetic medium deprived of uracil (H-ura) or trp (H-trp) (26). L-A and M1 virions were isolated and purified through CsCl gradient centrifugation as described in Ref. 27.

**Transcription Reaction**—The standard transcription reaction mixture contained 50 mM Tris–HCl, pH 7.5, 5 mM MgCl₂, 0.1 mM EDTA, 20 mM NaCl, 5 mM KCl, 1 mM diithiothreitol, 2.5 mg/ml benzonite, and 0.5 mM each of ATP, CTP, GTP, and UTP. When a radioactive nucleotide was used, the concentration was reduced to 20 μM. The reaction was started by the addition of purified L-A or M1 virions and incubated at 30 °C. The RNA products were extracted with phenol, phenol–chloroform, and precipitated with ethanol. Then, the RNA was separated in ether and 5% acrylamide gel, depending on the size of the products. Radioactive products were visualized by autoradiography. Nonradioactive RNA was detected by ethidium bromide staining or by Northern hybridization (28) using a 32P-labeled specific probe.

**Ski1p-TAP Purification**—Tandem affinity purification (TAP)-tagged Ski1p was expressed in strain 2928-4 (a ura3 trpl his3, L-A-o, L-BC) harboring plasmid pRE1004 by growing the cells in H-ura medium, in which glucose was substituted with 2% galactose. pRE1004 is a derivative of pEMBLyex4 (29) with a 5.3-kb BamHI fragment that contains the entire SKI1 coding sequence directly fused to TAP at the carboxyl terminus. The expression of the protein is under the control of the GAL1-CYC hybrid promoter. Ski1p-TAP was purified in a single-step purification with calmodulin affinity resin (Stratagene) (30, 31). Briefly, a cell lysate was prepared by breaking the cells with a FastPrep instrument (BIO101 Savant) in a buffer containing 20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 1× protease inhibitor (GE Healthcare) and clarified by centrifugation at 50,000 rpm for 1 h with a TLA100.2 rotor. The supernatant was dialyzed against IPP 150 calmodulin binding buffer (10 mM β-mercaptoethanol, 10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 mM magnesium acetate, 1 mM imidazole, 2 mM CaCl₂, and 0.1% Nonidet P-40) for 1 h and then incubated for 1 h with 200 μl calmodulin affinity resin pre-equilibrated with IPP 150 calmodulin binding buffer. The mixture was transferred to a column, and then the column was washed with 40 ml IPP 150 calmodulin binding buffer. The bound protein was eluted stepwise with IPP 150 calmodulin elution buffer (10 mM β-mercaptoethanol, 10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1 mM magnesium acetate, 1 mM imidazole, 2 mM EGTA, and 0.1% Nonidet P-40). The eluted protein was analyzed by SDS-PAGE followed by silver staining. Fraction 3 (see lane 4 in Fig. 6A) contained the highest concentration of Ski1p-TAP (0.09 mg/ml) among elutes, estimated by the Bradford method (32) using bovine serum albumin as standard.

**T7 Transcripts with Different 5'-Ends**—T7 transcripts with different 5’-ends were made by run-off transcription with T7 RNA polymerase as described in Ref. 33. 5’-monophosphorylated and capped RNAs were synthesized by the addition of an excess amount of GMP and m7GpppG cap analogue, respectively, over GTP. We used PvuII-digested pTF60 as template. pTF60 contains only two extra Gs between the T7 promoter and the entire X cDNA sequence (27). X (530 bp) is a mutant of L-A with a large internal deletion (34).

**Enzyme Digestion**—Terminator 5’-exonuclease or Ski1p-TAP digestion was carried out in a buffer containing 50 mM Tris–HCl, pH 8.0, 2 mM MgCl₂, 0.1 mM NaCl, and 0.5 units Terminator or 30 ng of Ski1p-TAP. RNA 5’-polyphosphatase consisted of the following: 50 mM HEPES KOH pH 7.5, 0.1 mM NaCl, 1 mM EDTA, 0.1% β-mercaptoethanol, 0.01% Triton X-100, and 10 units of the enzyme. S1 nuclease was made up of the following: 30 mM sodium acetate, pH 4.5, 60 mM NaCl, 1 mM ZnCl₂, and 20 units of S1. Bacterial alkaline phosphatase (BAP) consisted of the following: 10 mM Tris–HCl, pH 8.0, and 30 units of BAP. Tobacco acid pyrophosphatase consisted of the following: 50 mM sodium acetate, pH 6.0, 1 mM EDTA, 0.1% β-mercaptoethanol, 0.01% Triton X-100, and 5 units of the enzyme. All of the reactions were carried out at 37°C for 30 min, except that Terminator 5’-exonuclease and Ski1p-TAP were incubated at 30°C.

**Miscellaneous**—Radioactive nucleotides were obtained from PerkinElmer Life Sciences. Terminator 5’-exonuclease and RNA 5’-polyphosphatase were from Epicenter. S1 nuclease was from Promega, and BAP was from Invitrogen. Tobacco acid pyrophosphatase, γ-S-GTP, and β-S-GDP were from Sigma-Aldrich. The m7GpppG cap analogue was from Ambion, and malachite Green reagent was from Biolum.

**RESULTS**

**L-A Transcript Has Diphosphate at the 5’-End**—Purified L-A virions have RNA polymerase activity and synthesize full-length positive strand transcripts using the dsRNA genome as template. The RNA products were resistant to Terminator
5′-Diphosphate Terminus of L-A Transcript

The 5′-region of L-A positive strand starts with a G followed by an AU-rich sequence (Fig. 1B, upper diagram). The first U and C appear at positions 7 and 17, respectively. When L-A virions were incubated only with GTP and ATP, a short transcript (6 nt) was produced (Fig. 1B, lane 2). A further inclusion of UTP in the reaction increased the length to 16 nt (Fig. 1B, lane 3). These short transcripts were apparently released from the RNA polymerase complex because of the lack of incoming nucleotides for elongation. The addition of CTP at 30 min did not convert the 16-nt species into a full-size transcript (Fig. 1B, lane 9), and we did not observe these short transcripts when virions were incubated with four NTPs (Fig. 1B, lane 10). The 16-nt transcript has a single G at the 5′-end; therefore, only the 5′-terminal nucleotide in the molecule can be labeled with [α-32P]GTP. This transcript was purified from an acrylamide gel and treated with 5′-exonuclease. As shown in Fig. 1C, this species was resistant to the 5′-exonuclease but became sensitive to it after treatment with RNA 5′-polyphosphatase, a characteristic similar to the one observed with the full-size transcript. Then the 16-nt transcript labeled with [α-32P]GTP was digested with S1 nuclease and analyzed on PEI cellulose. S1 degrades single-stranded RNA endonucleolytically to yield 5′-phosphoryl terminated products. As shown in Fig. 1D (left panel), the labeled 5′-terminal nucleotide comigrated with GDP, indicating that the L-A transcript has a diphosphate at the 5′-end.

GDP Is Not Essential for Transcription Initiation—Incubation of L-A virions with ATP and [α-32P]UTP did not produce transcripts (Fig. 2A, lane 3), indicating that the guanine nucleotide is essential for initiation of transcription. dGTP also failed to initiate transcription (Fig. 2A, lane 8). Among the guanine nucleotides examined, GDP was the best substrate for the initiation reaction, consistent with the results that the 5′-end of the transcript is diphosphorylated. GMP also was incorporated well into the 16-nt transcript (Fig. 2A, lane 4). A cap analogue

5′-exonuclease (Fig. 1A, lane 2). The enzyme processively hydrolyzes single-stranded RNA with 5′-monophosphate in a 5′- to 3′-direction. Pretreatment with RNA 5′-polyphosphatase, however, converted the RNA to full sensitivity to the 5′-exonuclease (Fig. 1A, lane 4). The polyphosphatase removes the γ- and β-phosphates from 5′-triphosphorylated or -diphosphorylated RNA but has no activity on RNA with a 5′-cap. These results indicate that the L-A transcripts have no 5′-cap structure and suggest that the transcripts are tri- or diphosphorylated at their 5′-ends.

The 5′-region of L-A positive strand starts with a G followed by an AU-rich sequence (Fig. 1B, upper diagram). The first U and C appear at positions 7 and 17, respectively. When L-A virions were incubated only with GTP and ATP, a short transcript (6 nt) was produced (Fig. 1B, lane 2). A further inclusion of UTP in the reaction increased the length to 16 nt (Fig. 1B, lane 3). These short transcripts were apparently released from the RNA polymerase complex because of the lack of incoming nucleotides for elongation. The addition of CTP at 30 min did not convert the 16-nt species into a full-size transcript (Fig. 1B, lane 9), and we did not observe these short transcripts when virions were incubated with four NTPs (Fig. 1B, lane 10). The 16-nt transcript has a single G at the 5′-end; therefore, only the 5′-terminal nucleotide in the molecule can be labeled with [α-32P]GTP. This transcript was purified from an acrylamide gel and treated with 5′-exonuclease. As shown in Fig. 1C, this species was resistant to the 5′-exonuclease but became sensitive to it after treatment with RNA 5′-polyphosphatase, a characteristic similar to the one observed with the full-size transcript. Then the 16-nt transcript labeled with [α-32P]GTP was digested with S1 nuclease and analyzed on PEI cellulose. S1 degrades single-stranded RNA endonucleolytically to yield 5′-phosphoryl terminated products. As shown in Fig. 1D (left panel), the labeled 5′-terminal nucleotide comigrated with GDP, indicating that the L-A transcript has a diphosphate at the 5′-end.

GDP Is Not Essential for Transcription Initiation—Incubation of L-A virions with ATP and [α-32P]UTP did not produce transcripts (Fig. 2A, lane 3), indicating that the guanine nucleotide is essential for initiation of transcription. dGTP also failed to initiate transcription (Fig. 2A, lane 8). Among the guanine nucleotides examined, GDP was the best substrate for the initiation reaction, consistent with the results that the 5′-end of the transcript is diphosphorylated. GMP also was incorporated well into the 16-nt transcript (Fig. 2A, lane 4). A cap analogue
**5′-Diphosphate Terminus of L-A Transcript**

### Figure 2. Nucleotide Specificity of Transcription Priming

|   | ATP + [α-32P]UTP |
|---|------------------|
| A | GMP | GDP | None | GMP | GDP | TTP | m7GpppG | dGTP |
|   | 16 nt | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Ter Ex | + | - |

|   | ATP + [α-32P]UTP |
|---|------------------|
| B | GDP | m7GpppG |
|   | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| - | - | - | + | + | + | + | + | + |
| - | - | - | - | - | - | - | - | - |
| RPPase | PyroPase | Ter Ex |

**Legend:**
- **A**: Short transcripts (16 or 17 nt) were made by L-A virions in a CTP-omitted transcription reaction. The transcripts were labeled with [α-32P]UTP and primed without (None) or with 20 μM guanine nucleotides or their analogues as indicated above the panels. The products were separated in a 15% acrylamide gel and visualized by autoradiography. Some of the products were pretreated, before electrophoresis, with RNA 5′/H11032-phosphatase (Fig. 2B, lane 2), or Terminator 5′-exonuclease (Fig. 2B, lane 3) as indicated below the panels. It should be noticed that the cap analogue (m7GpppG)-primed transcripts migrate as 17-mer because of an extra G at the 5′-end (A, lane 7). Its size can be reduced to 16-mer by tobacco acid pyrophosphatase treatment (B, lane 7). D, the nucleotide sequence of the L-A positive strand at the 5′-end region is shown. The asterisks indicate the positions in the transcripts, which can be labeled with [α-32P]UTP in vitro.

(m7GpppG) could initiate transcription whose product run as a 17-mer because of the extra m7G at the 5′-end (Fig. 2A, lane 7). This 17-mer, unlike the GTP- or GDP-primed transcript, was resistant to the 5′-exonuclease even after treatment with RNA 5′-polynucleotidase (RPPase), or Terminator 5′-exonuclease (Ter Ex) as indicated below the panels. It should be noticed that the cap analogue (m7GpppG)-primed transcripts migrate as 17-mer because of an extra G at the 5′-end (A, lane 7). Its size can be reduced to 16-mer by tobacco acid pyrophosphatase treatment (B, lane 7). D, the nucleotide sequence of the L-A positive strand at the 5′-end region is shown. The asterisks indicate the positions in the transcripts, which can be labeled with [α-32P]UTP in vitro.

**Nucleoside Triphosphatase Activity Associated with L-A Virions**

The 5′-triphosphate of GTP was converted to diphosphate when the nucleotide was incorporated into the 5′-end of L-A transcript. It suggests that the L-A virion has RNA or nucleoside triphosphatase activity. It is known that the yeast CTL1 gene product possesses RNA triphosphatase activity (35). It localizes in the cytoplasm, but its physiological role is unknown. A ctl1Δ strain is viable and can harbor L-A virus. L-A virions isolated from this mutant had transcriptase activity and synthesized the 16-nt transcript in the absence of CTP (data not shown). The 16-nt transcript labeled with [α-32P]GTP was gel-purified and treated with S1 nuclease. As shown in Fig. 1D (right panel), the 5′-terminal nucleotide released by S1 digestion was GDP, indicating that the transcript had a diphosphate at its 5′ terminus. Therefore, CTL1 is not responsible for the conversion of triphosphate to diphosphate.

We found a weak nucleoside triphosphatase activity associated with L-A virions in a CsCl gradient (Fig. 4D). A gradient from an L-A-negative strain had no such activity (Fig. 4C). The L-A peak fraction (fraction 5) released a low amount of P, from
ATP or GTP alone, but its activity was stimulated greatly when both nucleotides were present together (supplemental Fig. 1SA). GTP can be replaced by GDP, \( \gamma \)-S-GTP, or \( \beta \)-S-GDP for stimulation, all of which can prime the transcription reaction, whereas a nonpriming nucleotide CTP failed to stimulate \( \Pi \) release (supplemental Fig. 1S, A and B). A potent inorganic pyrophosphatase activity has been observed to be associated with L-A virions (36). It is likely that the enhanced release of \( \Pi \) was not caused by nucleoside triphosphatase activity per se but by hydrolysis of inorganic pyrophosphate generated as a byproduct from polymerization of the 6-nt transcript (5′-GAAAAA).

Therefore, we carried out the reaction using [\( \alpha \)-32P]GTP and directly analyzed the products with PEI cellulose. As shown in Fig. 4E (lane 2), the L-A peak fraction (fraction 5) produced GDP, confirming its triphosphatase activity. In the presence of ATP, the label in GDP decreased, and a new radioactive spot migrating between GDP and GTP appeared (Fig. 4E, lane 4). We confirmed that the latter spot comigrated with the gel-purified 6-nt 5′-GAAAAA transcript. Because this transcript has a single \( G \) in the molecule, the results raise the possibility that GDP produced by the nucleoside triphosphatase activity was incorporated into its 5′-end, resulting in the concomitant loss of radioactivity in GDP. When a similar reaction was carried out by substituting ATP with CTP, however, the label in GDP again decreased by the addition of CTP (Fig. 4E, lane 4). Because CTP cannot support polymerization of even short transcripts without ATP and UTP, the results suggest that the decrease of GDP was not caused by its incorporation into RNA transcripts but by the competitive inhibition of the triphosphatase activity by ATP or CTP. It is also possible that unincorporated GDP was reconverted to GTP by virion-associated nucleoside diphosphate kinase (36).

**M1 Transcript Has Diphosphate at the 5′-End**—M1, a satellite RNA of L-A virus, utilizes L-A encoded proteins to encapsidate and replicate its RNA genome. M1 can replicate and be maintained in the cell without L-A virus if the viral proteins are provided from a vector. We isolated M1 virions from L-A virus-free cells to avoid the preparation from being contaminated with L-A virus. M1 virions purified through a CsCl gradient synthesized full-length M1 transcripts in the presence of four NTPs and produced a short 17-nt transcript when CTP was omitted (Fig. 5B). The 17-nt transcript labeled with [\( \alpha \)-32P]GTP was purified through an acrylamide gel, treated with S1 nuclease, and analyzed by PEI cellulose chromatography. As shown in Fig. 5C, lane 2, the transcript produced two spots corresponding to GDP and GMP, and their ratio was 1:2.1. In addition to the 5′-terminal \( G \), the 17-nt transcript has two additional \( G \)s (Fig. 5A), and these internal \( G \)s are expected to be released as GMP upon S1 digestion. The results, therefore, suggest that GDP was derived from the 5′-end of the transcript and that the transcript thus has diphosphate at the 5′-end. To confirm that GDP was derived from the 5′-end, the 17-nt transcript was treated with RNA 5′-polyphosphatase, ethanol-precipitated, and then digested with S1 nuclease. As shown in Fig. 5C (lane 3), now, the transcript only produced GMP, indicating that GDP was really released from the 5′-end.

**5′-Diphosphorylated L-A Transcript Is Resistant to Ski1p 5′-Exonuclease**—The L-A transcript has a diphosphate at the 5′-end. We wondered whether the viral transcript is susceptible to Ski1p 5′-exonuclease. A. Stevens purified this enzyme and performed an extensive biochemical analysis on it. It is now well known that the nuclease digests 5′-monophosphorylated RNA as substrate but works poorly on 5′-triphosphorylated or capped RNA (37). However, we did not find information on its reactivity toward 5′-diphosphorylated RNA. We, therefore, purified Ski1p as a TAP fusion protein from yeast cells by one-step purification using calmodulin-affinity resin following the
method described in Ref. 31. Fig. 6A shows the elution profile of Ski1p from the affinity resin visualized by silver staining. RNA substrates with different 5′ termini but having the same nucleotide sequence were made in vitro using T7 RNA polymerase and served to test the specificity of the purified enzyme. As shown in Fig. 6B, the protein efficiently digested 5′-monophosphorylated RNA (lane 4) but hardly worked on 5′-triphosphorylated (lane 2) or capped RNA (lane 6), confirming the specificity ascribed to the enzyme. We made the 16-nt L-A transcript in vitro by incubating L-A virions in a CTP-omitted transcription reaction and treated it with purified Ski1p. As shown in Fig. 6C, the transcript was largely resistant to Ski1p (lane 2) but became completely digested with the enzyme after pretreatment with RNA 5′-polyphosphatase (lane 4), the same digestion pattern observed with the commercially available Terminator 5′-exonuclease (Fig. 1C). From these results, we concluded that L-A viral transcript made in vitro is a poor substrate for the Ski1p 5′-exonuclease.

**DISCUSSION**

In this work, we have demonstrated that L-A transcripts made in vitro by L-A virions are 5′-diphosphorylated. More significantly, irrespective of whether transcription was primed by GTP or GMP, the guanine nucleotide incorporated at the 5′ terminus was diphosphorylated. Thus, the virus deliberately synthesizes RNA transcript with 5′-diphosphate. M1, a satellite RNA of L-A virus, utilizes Gag and Gag-Pol of the helper virus to encapsidate and replicate its RNA genome. Isolated M1 virions likewise synthesized transcripts with 5′-diphosphate. We also have demonstrated that the L-A transcript made in vitro is a poor substrate for the Ski1p 5′-exonuclease. When the 5′-end of the transcript was converted from diphosphate to monophosphate, however, Ski1p efficiently digested it. Previously, we observed that the deletion of SKI1 resulted in a 5–10-fold increase in the copy number of L-A virus and that overexpression of Ski1p cured L-A virus from the cell at a high frequency (22). Because Ski1p is the major exonuclease involved in mRNA degradation in the budding yeast (19), our results suggest that the virus makes its transcript 5′-diphosphorylated apparently to protect it from a direct attack of the potent Ski1p. Our results also suggest that the host cell possesses an RNA diphosphatase activity in the cytoplasm to convert the viral transcript from diphosphate to monophosphate at the 5′-end. Consistent with this view is that in ski1Δ strains L-A transcripts accumulate in large amounts and can be detected easily by Northern hybridization. Furthermore, these transcripts are 5′-monophosphorylated, as judged from their susceptibility to Terminator 5′-exonuclease or purified Ski1p.3 In wild type strains, these transcripts are quickly digested by Ski1p and do not accumulate in large quantities. These observations suggest that in a hypothetical RNA diphosphatase-negative strain, viral transcripts will be stabilized because of the inability of Ski1p to directly attack them. Thus, these mutants are expected to exhibit a superkiller phenotype when harboring the satellite M1 dsRNA.

3 T. Fujimura and R. Esteban, unpublished results.
The 5′-end region of M1 transcript. The first C appears at position 18. M1 virions make a 17-nt transcript in a CTP-omitted transcription reaction as shown in B. In this gel system (15% acrylamide), the 17-nt transcript comigrates with bromphenol blue (BPB). The asterisks in A indicate three positions in the 17-nt transcript, which can be labeled with [α-32P]GTP. Upon S1 nuclease digestion, the two internal Gs in the transcript will be released as GMP, while the 5′-terminal G would be GDP if the transcript has diphosphate at the 5′-end. C, the [α-32P]GTP-labeled M1 17-nt transcript was isolated from an acrylamide gel and treated with S1 nuclease. The digest was analyzed on PEI cellulose with 1 M LiCl (lane 2). The ratio of radioactive label in GDP and GMP quantified by phosphorimaging was 1:2.1. Lane 1 indicates the non-S1 digested sample. In lane 3, the 17-nt transcript was first treated with RNA 5′-polyphosphatase to eliminate the β-phosphate at the 5′-end. After ethanol precipitation, the transcript was digested with S1 nuclease. RPPase, RNA 5′-polyphosphatase.

Another possible role for the 5′-diphosphate status of the viral transcript is on translation and is more speculative. Here, we demonstrated that the cap analogue m7GpppG can be used to prime transcription in vitro by L-A virions. Barbone et al. (38) reported that viral transcripts made in vitro in the presence of the cap analogue are translated in a yeast cell-free translation system 8–15-fold more efficiently than the ones made in its absence, although they failed to directly prove its incorporation into viral transcripts. These data together suggest that viral transcripts with 5′-diphosphate are poor templates for translation but that the incorporation of the cap structure at the 5′-end converted them to more efficient templates. In the mRNA-capping reaction, RNA guanylyltransferase transfers GMP to the diphosphate end of pre-mRNA through a covalent enzyme-GMP intermediate. It has been known that L-A Gag protein binds to 5′-capped mRNAs and forms a covalent bond with m7GMP through Lys but not His. However, it recently has been demonstrated that in the capping reaction of vesicular stomatitis virus, L protein forms an intermediate by covalently binding the 5′-monophosphorylated pre-mRNA through His and transfers the bound pre-mRNA to GDP (41). It appears that members of the alphavirus-like superfamily also utilize His to form a phosphamide bond with m7GMP and transfer the m7GMP moiety to the 5′-diphosphate end of a viral transcript during the capping reaction (42–44). L-A Gag with mutations at His-154 failed to form a covalent bond with m7GMP but did not affect replication and maintenance of M1 (25). Therefore, those reactions, including transcription (+) strand RNA synthesis), encapsidation of the (+) strand into the virion, and (−) strand synthesis inside the virion, are not affected by the mutations. Furthermore, M1 virions with a mutant Gag (Arg-154) synthesize M1 transcripts with 5′-diphosphate as wild type virions do. Interestingly, however, the expression of M1-encoded killer toxin is severely compromised in vivo by the mutations at His-154 (25), suggesting a specific role of His-154 on translation. Therefore, these data fit well within the framework of this capping hypothesis.

We observed a weak nucleoside triphosphatase activity associated with L-A virions. However, it is not clear whether this activity is involved in the synthesis of the 5′-diphosphorylated transcript primed with GTP. RNA polymerase may preferentially incorporate GDP generated by nucleoside triphosphatase over GTP to prime transcription. The poly-

5′-Diphosphate Terminus of L-A Transcript

FIGURE 5. M1 transcript also has diphosphate at the 5′-end. A, the 5′-end region of M1 transcript. The first C appears at position 18. M1 virions makes a 17 nt transcript in a CTP-omitted transcription reaction as shown in B. In this gel system (15% acrylamide), the 17 nt transcript comigrates with bromphenol blue (BPB). The asterisks in A indicate three positions in the 17 nt transcript, which can be labeled with [α-32P]GTP. Upon S1 nuclease digestion, the two internal Gs in the transcript will be released as GMP, while the 5′-terminal G would be GDP if the transcript has diphosphate at the 5′-end. C, the [α-32P]GTP-labeled M1 17 nt transcript was isolated from an acrylamide gel and treated with S1 nuclease. The digest was analyzed on PEI cellulose with 1 M LiCl (lane 2). The ratio of radioactive label in GDP and GMP quantified by phosphorimaging was 1:2.1. Lane 1 indicates the non-S1 digested sample. In lane 3, the 17 nt transcript was first treated with RNA 5′-polyphosphatase to eliminate the β-phosphate at the 5′-end. After ethanol precipitation, the transcript was digested with S1 nuclease. RPPase, RNA 5′-polyphosphatase.

Another possible role for the 5′-diphosphate status of the viral transcript is on translation and is more speculative. Here, we demonstrated that the cap analogue m7GpppG can be used to prime transcription in vitro by L-A virions. Barbone et al. (38) reported that viral transcripts made in vitro in the presence of the cap analogue are translated in a yeast cell-free translation system 8–15-fold more efficiently than the ones made in its absence, although they failed to directly prove its incorporation into viral transcripts. These data together suggest that viral transcripts with 5′-diphosphate are poor templates for translation but that the incorporation of the cap structure at the 5′-end converted them to more efficient templates. In the mRNA-capping reaction, RNA guanylyltransferase transfers GMP to the diphosphate end of pre-mRNA through a covalent enzyme-GMP intermediate. It has been known that L-A Gag protein binds to 5′-capped mRNAs and forms a covalent bond with m7GMP through His-154 while releasing the mRNA body (25, 39). This raises the possibility that the m7GMP attached to His-154 can be transferred to the diphosphate end of an emerging viral transcript, thus forming a 5′-cap structure on the RNA. A 5′-capped species of viral RNA has not been detected yet (40) presumably because the efficiency of transfer is low. This cap-snatching hypothesis originally was described in Ref. 25. In the conventional capping reaction, guanylyltransferase forms a covalent bond with GMP through Lys but not His. However, it recently has been demonstrated that in the capping reaction of vesicular stomatitis virus, L protein forms an intermediate by covalently binding the 5′-monophosphorylated pre-mRNA through His and transfers the bound pre-mRNA to GDP (41). It appears that members of the alphavirus-like superfamily also utilize His to form a phosphamide bond with m7GMP and transfer the m7GMP moiety to the 5′-diphosphate end of a viral transcript during the capping reaction (42–44). L-A Gag with mutations at His-154 failed to form a covalent bond with m7GMP but did not affect replication and maintenance of M1 (25). Therefore, those reactions, including transcription (+) strand RNA synthesis), encapsidation of the (+) strand into the virion, and (−) strand synthesis inside the virion, are not affected by the mutations. Furthermore, M1 virions with a mutant Gag (Arg-154) synthesize M1 transcripts with 5′-diphosphate as wild type virions do. Interestingly, however, the expression of M1-encoded killer toxin is severely compromised in vivo by the mutations at His-154 (25), suggesting a specific role of His-154 on translation. Therefore, these data fit well within the framework of this capping hypothesis.

We observed a weak nucleoside triphosphatase activity associated with L-A virions. However, it is not clear whether this activity is involved in the synthesis of the 5′-diphosphorylated transcript primed with GTP. RNA polymerase may preferentially incorporate GDP generated by nucleoside triphosphatase over GTP to prime transcription. The poly-

5′-Diphosphate Terminus of L-A Transcript

FIGURE 6. L-A transcript made in vitro is resistant to Ski1p. A, purification of Ski1p. Ski1p-TAP was purified through a calmodulin affinity resin column. The bound protein was eluted stepwise with a buffer containing EGTA. Protein was separated with SDS-PAGE and visualized by silver staining. Lane 1, the last wash of the column. Lanes 2–7, fractions eluted with EGTA. M, molecular standards (kDa). B, specificity of purified Ski1p. Transcripts bearing a 5′-pppG-, 5′-pG-, or 5′-cap structure were made in vitro by T7 RNA polymerase using the same DNA template as described under “Experimental Procedures.” The transcripts were incubated with Ski1p, and the digest was separated in an agarose gel and visualized by ethidium bromide staining. C, the 32P-labeled 16 nt transcript was made in vitro by L-A virions in a CTP-omitted transcription reaction and treated with RNA 5′-polyphosphatase (RPPase) and/or purified Ski1p as indicated below the panel. Then, the transcript was separated in a acrylamide gel and visualized by autoradiography.
merase itself may be able to convert GTP to GDP during transcription initiation. Finally, the conversion may occur post-transcriptionally on the nascent transcript during its release from the virion through a pore in the capsid. Our data indicate that the host CTI1 RNA triphosphatase is not involved in this process. The conversion from triphosphate to diphosphate, however, is not essential for the initiation of transcription process. The conversion from triphosphate to diphosphate, however, is not essential for the initiation of transcription. The conversion from triphosphate to diphosphate, however, is not essential for the initiation of transcription. Finally, the conversion may occur post-

Acknowledgment—We thank Dr. Reed B. Wickner for providing the V-A transcript.

REFERENCES
1. Furushita, Y., and Shatkin, A. J. (2000) Adv. Virus Res. 55, 135–184
2. Shuman, S. (2001) Prog. Nucleic Acid Res. Mol. Biol. 66, 1–40
3. Koonin, E. V., and Moss, B. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 3283–3289
4. Rehwinkel, J., Tan, C. P., Goubad, D., Schulz, O., Pichlmair, A., Bier, K., Robb, N., Vrede, F., Barclay, W., Fodor, E., and Reis e Sousa, C. (2010) Cell 140, 397–408
5. Schmidt, A., Schwerd, T., Hamm, W., Hellmuth, J. C., Cui, S., Wenzel, M., Hoffmann, F. S., Michalct, M. C., Besch, R., Hopfen, K. P., Endres, S., and Rothenfusser, S. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 12067–12072
6. Wickner, R. B. (2007) in Fields Virology (Knipe, D. M., and Howley, P. M., eds.) 5th Ed., pp. 737–768, Lippincott Williams & Wilkins, Philadelphia, PA
7. Fujimura, T., and Wickner, R. B. (1988) Cell 55, 663–671
8. Icho, T., and Wickner, R. B. (1989) J. Biol. Chem. 264, 6716–6723
9. Dinman, J. D., Icho, T., and Wickner, R. B. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 174–178
10. Cheng, R. H., Caston, J. R., Wang, G. J., Gu, F., Smith, T. J., Baker, T. S., Bozarth, R. F., Trus, B. L., Cheng, H., Wickner, R. B., and Steven, A. C. (1994) J. Mol. Biol. 244, 255–258
11. Caston, J. R., Trus, B. L., Booy, F. P., Wickner, R. B., Wall, J. S., and Steven, A. C. (1997) J. Cell Biol. 138, 975–985
12. Fujimura, T., Esteban, R., and Wickner, R. B. (1986) Proc. Natl. Acad. Sci. U.S.A. 83, 4433–4437
13. Tipper, D. J., and Bostian, K. A. (1984) Microbiol. Rev. 48, 125–156
14. Toh, E., Guerry, P., and Wickner, R. B. (1978) J. Bacteriol. 136, 1002–1007
15. Ridley, S. P., Sommer, S. S., and Wickner, R. B. (1984) Mol. Cell. Biol. 4, 761–770
16. Parker, R., and Song, H. (2004) Nature Struct. Mol. Biol. 11, 121–127
17. Wills, C. J., Wormington, M., and Peltz, S. W. (2001) Nat. Rev. Mol. Cell. Biol. 2, 237–246
18. Mitchell, P., Petfalski, E., Shevchenko, A., Mann, M., and Tollervey, D. (1997) Cell 91, 457–466
19. Anderson, J. S., and Parker, R. P. (1998) EMBO J. 17, 1497–1506
20. Widner, W. R., and Wickner, R. B. (1993) Mol. Cell. Biol. 13, 4331–4341
21. Searfoss, A. M., and Wickner, R. B. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 9133–9137
22. Fujimura, T., Esteban, R., and Wickner, R. B. (2008) J. Biol. Chem. 283, 25812–25820
23. Brunn, J., and Keitz, B. (1976) Nucleic Acids Res. 3, 2427–2436
24. Nemiroff, M. E., and Brunn, J. A. (1987) J. Biol. Chem. 262, 6785–6787
25. Blanch, A., Ribas, J. C., Wickner, R. B., and Sonenberg, N. (1994) Mol. Cell. Biol. 14, 2664–2674
26. Wickner, R. B. (1980) Cell 21, 217–226
27. Fujimura, T., and Wickner, R. B. (1992) J. Biol. Chem. 267, 2708–2713
28. Fujimura, T., Esteban, R., Esteban, L. M., and Wickner, R. B. (1990) Cell 62, 819–828
29. Dente, L., Sollazzo, M., Baldari, C., Cesareni, G., and Cortese, R. (1985) in DNA Cloning (Glover, D. M., ed) Vol. 1. pp. 101–107, IRL Press, London
30. Puig, O., Caspary, F., Rigaut, G., Rutz, B., Bouvetier, E., Bragado-Nilsson, E., Wilim, M., and Séraphin, B. (2001) Methods 24, 218–229
31. Cheng, C. P., Serviene, E., and Nagy, P. D. (2006) J. Virol. 80, 2631–2640
32. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
33. Pellegrini, O., Mathy, N., Condon, C., and Bénaud, L. (2008) Methods Enzymol. 418, 167–183
34. Fujimura, R., Fujimura, T., and Wickner, R. B. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 4411–4415
35. Rodriguez, C. R., Takagi, T., Cho, E. J., and Buratowski, S. (1999) Nucleic Acids Res. 27, 2181–2188
36. Georgopoulos, D. E., and Leibowitz, M. J. (1987) Yeast 3, 117–129
37. Stevens, A. (2001) Methods Enzymol. 342, 251–259
38. Barbone, F. P., Williams, T. L., and Leibowitz, M. J. (1992) Virolgy 187, 333–337
39. Blanch, A., Goyer, C., and Sonenberg, N. (1992) Mol. Cell. Biol. 12, 3390–3398
40. Massion, D. C., Blanch, A., Ribas, I. C., Carroll, K., Sonenberg, N., and Wickner, R. B. (1995) Mol. Cell. Biol. 15, 2763–2771
41. Ogino, T., Yadav, S. P., and Banerjee, A. K. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 3463–3468
42. Akita, T., Laakkonen, P., Vihtanen, H., and Kääriäinen, L. (1997) J. Virol. 71, 392–397
43. Fujimura, T., and Ahlquist, P. (1999) J. Virol. 73, 10061–10069
44. Huang, Y. L., Han, Y. T., Chang, Y. T., Hsu, Y. H., and Meng, M. (2004) J. Virol. 78, 1271–1280
45. Fujimura, T., Ribas, J. C., and Wickner, R. B. (1992) Nature 359, 746–749

5'-Diphosphate Terminus of L-A Transcript